Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says

MT Newswires Live

07/27

Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.

The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.

RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.

The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.

RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.

Shares of the company were down more than 14% in Monday trading.

Price: 18.97, Change: -3.26, Percent Change: -14.65

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2654104947"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654104947\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654104947?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 23:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654104947","market":"us","top_or_hot":-1,"title":"Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.</p><p>The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.</p><p>RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.</p><p>The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.</p><p>RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.</p><p>Shares of the company were down more than 14% in Monday trading.</p><p>Price: 18.97, Change: -3.26, Percent Change: -14.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-07-27 23:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.</p><p>The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.</p><p>RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.</p><p>The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.</p><p>RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.</p><p>Shares of the company were down more than 14% in Monday trading.</p><p>Price: 18.97, Change: -3.26, Percent Change: -14.65</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAR","symbol_name":"安飛士","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654104947","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654104947","pubTimestamp":1785166365,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Legend Biotech's  data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.Shares of the company were down more than 14% in Monday trading.Price: 18.97, Change: -3.26, Percent Change: -14.65","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAR":"安飞士","BK4139":"生物科技","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","XBI":"SPDR S&P Biotech ETF","LEGN":"传奇生物","BK4022":"陆运","MEMS":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4230":"旅客陆运","BK4505":"高瓴资本持仓","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4588":"碎股","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4207":"综合性银行","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","CANC":"TEMA ONCOLOGY ETF","BK4581":"高盛持仓","MEDI":"HARBOR HEALTH CARE ETF","BK4585":"ETF&股票定投概念","GSIB":"THEMES GLOBAL SYSTEMICALLY IMPORTANT BANKS ETF"},"translate_title":"加拿大皇家银行资本市场表示，传奇生物的体内 CAR-T 细胞治疗数据验证了该方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5,"MEDI":0.6,"CANC":0.6,"LEGN":1.5,"MEMS":0.6,"GSIB":0.6,"XBI":1.5},"content_text":"Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.Shares of the company were down more than 14% in Monday trading.Price: 18.97, Change: -3.26, Percent Change: -14.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}